![](https://pharmashots.com/public/default-image/default-730x400.png )
Xenon Pharmaceutical Reports Positive Results of XEN1101 P-1b TMS (transcranial magnetic stimulation) study
Shots:
- This study enrolled 20 healthy males while measuring endpoint at 2- 4 & 6hrs. administering 20mg of XEN1101 or PBO showing its safety and tolerability
- P-Ib TMS results: TMS-EMG measure- single 20mg of XEN1101 resulted in (plasma levels of 15.7 -30.2 and 44.4 ng/mL at 2- 4 & 6hrs.); RMT (1.5±0.4%- 3.0±0.7%- 4.3±0.8%)
- With completion of XEN1101 P-I it is expected to initiate P-II trial- a treatment for adult focal seizures in Q4’18
Ref: Xenon | Image: Society of generic physiologists
Click here to read the full press release
![](https://pharmashots.com/public/images/Senior-2023-08-17-64ddc3af74ec4.png)
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com